Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1998-07-22
2001-10-30
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S009200, C435S007940, C436S506000
Reexamination Certificate
active
06309847
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to methods for the treatment of T cell mediated diseases, such as Type I diabetes, also known as insulin-dependent diabetes mellitus (IDDM), and to methods for detecting and/or monitoring the effectiveness of such treatment.
BACKGROUND OF THE INVENTION
Type I diabetes, or IDDM, is an autoimmune disease caused by T cells that attack and destroy the insulin-producing cells located in the islets of the pancreas (Castano and Eisenbarth, 1990). The autoimmune process culminating in IDDM begins and progresses without symptoms. The disease surfaces clinically only when the cumulative loss of &bgr;-cells exceeds the capacity of the residual &bgr;-cells to supply insulin. Indeed, the collapse of glucose homeostasis and clinical IDDM is thought to occur only after 80-90% of the &bgr;-cells have been inactivated by the immune system. Thus, patients who can be identified as suffering from IDDM are bound to be in an advanced stage of autoimmune destruction of their &bgr;-cells. Moreover, diagnosis of incipient, pre-clinical diabetes by the detection of immunological markers of &bgr;-cell autoimmunity can be made only after the onset of the autoimmune process. Therefore, the therapeutic quest is to find a safe, specific and effective way to turn off an autoimmune process that is already well underway.
The present inventors have examined this question before by studying the spontaneous diabetes developing in mice of the NOD strain, which is considered to be a faithful model of human IDDM (Castano and Eisenbarth, 1990). The spontaneous autoimmune process resulting in diabetes in the NOD mouse is first detectable as a mild insulitis beginning at about 1 month of age. In most female mice, the insulitis progresses towards a penetrating intra-islet infiltrate that leads to &bgr;-cell damage and overt insulin-dependent diabetes mellitus (IDDM) that surfaces at about 4-5 months of age, (Bach, 1991). The insulitis is associated with T-cell autoreactivity and autoantibodies to a variety of self-antigens (Harrison, 1992). It has been assumed that one of the autoantigens is the primary target for an insulitis which could activate autoimmunity to additional, secondary self-antigens. The T-cell response to glutamic acid decarboxylase (GAD) was reported to be detectable before the T-cell responses to hsp60 and to other antigens (Kaufman et al., 1993; Tisch et al., 1993) and the administration of GAD by intrathymic injection at 3 days of age (Kaufman et al., 1993), or by intravenous injection at 3 weeks of age (Tisch et al., 1993), was found to inhibit the development of T-cell reactivity to the other self-antigens, including hsp60, and to prevent diabetes. The investigators concluded that autoimmunity to GAD might be the primary event leading to diabetes. However, a variety of seemingly “non-specific” manipulations applied early in the course of insulitis can prevent or delay the later development of diabetes (Bowman et al., 1994).
In addition to the GAD antigen, autoimmunity to hsp60 has been shown to have a functional role in NOD diabetes (PCT Patent Publication No. WO 90/10449): T cells responsive to the hsp60 peptide p277 could adoptively transfer diabetes or, when attenuated, could vaccinate mice against diabetes (Elias et al., 1991); and a single, subcutaneous administration of peptide p277 in oil either early (Elias et al., 1991) or very late in the autoimmune process (Elias et al., 1994) could arrest the disease.
T cells of the CD4 “helper” type have been divided into two groups by the characteristic cytokines they secrete when activated (Mosmann et al., 1989). TH1 cells secrete IL-2, which induces T-cell proliferation, and cytokines such as IFN&ggr;, which mediate tissue inflammation; TH2 cells, in contrast, secrete IL-4 and IL-10. IL-4 helps &bgr;-cells secrete antibodies of certain IgG isotypes and suppresses the production of TH1 inflammatory cytokines (Banchereau et al., 1994). IL-10 indirectly inhibits TH1 activation by affecting antigen-presentation and inflammatory cytokine production by macrophages (Moore et al., 1993).
It has now been discovered by the laboratory of the present inventors that the successful treatment of the autoimmune process in IDDM by administration of the peptide p277 in oil is caused by the effect of this treatment in aborting TH1-type autoimmunity to several different antigens and instead activating p277 autoimmunity into a TH2 mode. Thus, a disease with a spectrum of autoreactivities can be turned off with a single peptide capable of inducing a T cell cytokine shift.
SUMMARY OF THE INVENTION
It is an object of the present invention to determine or monitor the effectiveness of treatment of a T cell mediated disease by means of testing, in an appropriate animal model, for a shift from a TH1 cell response to a TH2 T cell response over time. This may be accomplished by detecting a shift in the antibody isotype from IgG2a to IgG1 and IgG2b isotype antibodies, or detecting a shift from the proliferation of the cytokines from IL-2 and IFN&ggr; to IL-4 and IL-10.
It is a further object of the present invention to determine optimum vaccine dosages and regimens by measuring for an optimal shift from a TH1 T cell cytokine response to a TH2 T cell cytokine response.
REFERENCES:
patent: 5658744 (1997-08-01), Ochoa et al.
Burstein et al, J. Exp. Med., 177, 457-463, 1993.*
De Wit et al, J. Exp. Med., 175, 9-14, 1992.*
Secrist et al, J. Exp. Med., 178, 2123-2130, 1993.*
Allen et al, Immunology Today, 18, 387-392, 1997.*
Liblau et al, Immunology Today, 16, 34-38, 1995.*
McFarland, Science, 274, 2037-2038, 1996.*
Harrison, Leonard C., “Islet cell antigens in insulin-dependent diabetes: Pandora's box revisited.”, Immunology Today, vol. 13, pp. 348-352 (1992).
Kaufman, Daniel et al., “Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes.”, Nature, vol. 366, pp. 69-72 (1993).
Tisch, Roland et al., “Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.”, Nature, vol. 366, pp. 72-75 (1993).
Bowman, Mark A. et al., “Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease.”, Immunology, vol. 15, No. 3, pp. 115-120 (1994).
Elias, Dana et al., “Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein.”, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 3088-3091 (1991).
Elias, Dana et al., “Peptide therapy for diabetes in NOD mice.”, The Lancet, vol. 343, pp. 704-706 (1994).
Pennline, Kenneth et al., “Recombinant human il-10 prevents the onset of diabetes in the nonobese diabetic mouse.”, Clinical Immunology and Immunopathology, vol. 72, No. 2, pp. 169-175 (1994).
Weiner, Howard L., “Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens.”, Annu. Rev. Immunol., pp. 809-837 (1994).
Rabinovitch, Alex., “Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM.”, Perspectives in Diabetes, vol. 43, pp. 613-621 (1994).
Solimena, Michele et al., “From TH1 to TH2: diabetes immunotherapy shifts gears.”, Nature Medicine, vol. 2, No. 12, pp. 1311-1312 (1996).
Cohen Irun R.
Elias Dana
Saunders David
Winston & Strawn
Yeda Research and Development Co. Ltd.
LandOfFree
Method for detecting or monitoring the effectiveness of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for detecting or monitoring the effectiveness of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for detecting or monitoring the effectiveness of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2593773